Guide for Authors

  • All journal information and instructions compiled in one document (PDF) in just one mouse-click Author information pack

    INTRODUCTION
    • Types of paper
    BEFORE YOU BEGIN
    • Ethics in publishing
    • Policy and ethics
    • Conflict of interest
    • Conflict of interest
    • Submission declaration
    • Authorship
    • Changes to authorship
    • Copyright
    • Role of the funding source
    • Funding body agreements and policies
    • Open access
    • Language (usage and editing services)
    • Submission
    • Referees
    PREPARATION
    • NEW SUBMISSIONS
    • References
    • Formatting requirements
    • REVISED SUBMISSIONS
    • Article structure
    • Essential title page information
    • Graphical abstract
    • Highlights
    • Footnotes
    • Artwork
    • Tables
    • References
    • Video data
    • AudioSlides
    • Supplementary data
    • Submission checklist
    • Additional Information
    AFTER ACCEPTANCE
    • Use of the Digital Object Identifier
    • Online proof correction
    • Offprints
    • Offprints
    • Standard abbreviations
    AUTHOR INQUIRIES

    Your Paper Your Way
    your paper your way



    Translational Proteomics covers all areas of human proteomics using multi-disciplinary approaches to untangle complex disease processes. Emphasis is placed on linking basic sciences to clinical research (from patient to bench to bedside). It focuses on the rapid dissemination of novel discoveries. Topics included but not limited to are:


    • Translational Systems Biology and Integrative Bioinformatics
    • Clinical Proteomics and Personalized medicine
    • Comparative proteomics and drug development
    • Medical bioinformatics and biostatistics
    • Biomarkers
    • Food and Health

    Translational Proteomics is intended to academic, industrial and clinical researchers, physicians, pharmaceutical scientists, biochemists, clinical chemists, disease molecular biologists in the fields of applied human proteomics. Examples of diseases include oncology, neurology, immunity, cardiovascular disease, infectious diseases and any internal medicine disorder.

    Types of paper

    The following types of paper are published:


    Original Articles: Original articles are the normal medium of publication. Proteomics discovery should not be only verified on a small cohort of patients, but most importantly must be validated on a few hundreds of patients with deep statistical analysis. Although there is no fixed length, articles should be as concise as possible, while providing sufficient information for the work to be repeated and for the claims of the authors to be judged by the readers.

    Mandatory requirements for reporting of clinical biomarker studies:

    1) A clinical biomarker is only relevant in specific contexts of use per disease, it must have a potential to improve the current state of the art (either being of added value, or based on its sole performance), and its application must be linked to a clear change in patient management. As such, the specific proposed context of use of the presented biomarker must be clearly provided and the expected practical consequence of the biomarker application should be discussed.
    2) A biomarker can only be assessed in an independent (ideally blinded) test set, containing sufficient samples to demonstrate significant value and justify relevant claims regarding biomarker use. Assessment of performance in a discovery set is inappropriate.
    3) This initial independent validation and performance assessment has to be performed in samples that reflect the typical clinical situation depending on the targeted context of use.
    4) Authors submitting clinical biomarker studies should address the above points in the cover letter, so that the Editor can assess and evaluate if the submitted manuscript fulfils the requirements for publication in Journal of Proteomics.

    Reviews: These are contributed by scientists who are leading specialists in their disease field of expertise, normally at the invitation of the Editors. Authors wishing to contribute a review paper are advised first to contact the Editor in Chief (to avoid overlap with Reviews already commissioned).


    News & Views: News & Views point out the author(s) vision of the character and importance of a new direction in traslational proteomics research. They are not intended to be accounts or analyses of an individual's personal research. Although News & Views will usually be invited, they can be submitted without invitation. Author(s) are encouraged to suggest experts in the field who can act as reviewers.


    Letters to the Editor: Letters to the Editor are intended to stimulate discussion and debate in areas of general concern and controversy in translational proteomics, and generally reflect the personal opinions of the author(s). They should be written in a continuous style and should normally not exceed two printed pages and contain no more than one figure or table.

    Ethics in publishing

    For information on Ethics in publishing and Ethical guidelines for journal publication see http://www.elsevier.com/publishingethics and http://www.elsevier.com/journal-authors/ethics.

    Policy and ethics

    The work described in your article must have been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans http://www.wma.net/en/30publications/10policies/b3/index.html; EU Directive 2010/63/EU for animal experiments http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm; Uniform Requirements for manuscripts submitted to Biomedical journals http://www.icmje.org. This must be stated at an appropriate point in the article.

    Conflict of interest

    All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. See also http://www.elsevier.com/conflictsofinterest. Further information and an example of a Conflict of Interest form can be found at: http://help.elsevier.com/app/answers/detail/a_id/286/p/7923.

    Conflict of interest

    Translational Proteomics follows the ICMJE recommendations regarding conflict of interest disclosures. All authors are required to report the following information with each submission: (1) All third-party financial support for the work in the submitted manuscript. (2) All financial relationships with any entities that could be viewed as relevant to the general area of the submitted manuscript. (3) All sources of revenue with relevance to the submitted work who made payments to you, or to your institution on your behalf, in the 36 months prior to submission. (4) Any other interactions with the sponsor of outside of the submitted work should also be reported. (5) Any relevant patents or copyrights (planned, pending, or issued). (6) Any other relationships or affiliations that may be perceived by readers to have influenced, or give the appearance of potentially influencing, what you wrote in the submitted work. As a general guideline, it is usually better to disclose a relationship than not. This information will be acknowledged at publication in a Transparency Document link directly in the article. Additional information on the ICMJE recommendations can be found at: http://www.icmje.org/. The form for conflict of interest disclosure can be downloaded here: http://www.icmje.org/coi_disclosure.pdf (if this link does not display properly in your browser, please right-click the link and select "Save Target As..." or "Save Link as..." from the pop-up menu).

    Submission declaration

    Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see http://www.elsevier.com/postingpolicy), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.

    Authorship

    All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

    Changes to authorship

    This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:
    Before the accepted manuscript is published in an online issue: Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.
    After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

    Copyright

    Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' where authors will retain copyright (for more information on this see http://www.elsevier.com/OAauthoragreement.). Permitted reuse of open access articles is determined by the author's choice of user license (see http://www.elsevier.com/openaccesslicenses).

    Retained author rights
    As an author you (or your employer or institution) retain certain rights, including copyright; for details you are referred to http://www.elsevier.com/OAauthoragreement.

    Role of the funding source

    You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

    Funding body agreements and policies

    Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit http://www.elsevier.com/fundingbodies.

    Open access

    This journal is fully open access; all articles will be immediately and permanently free for everyone to read and download upon publication. Permitted (re)use is defined by your choice of one of the following Creative Commons user licenses (see http://www.elsevier.com/about/open-access/open-access-policies/oa-license-policy):

    Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

    Creative Commons Attribution-NonCommercial-ShareAlike (CC BY-NC-SA): for non-commercial purposes, lets others distribute and copy the article, to create extracts, abstracts and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text and data mine the article, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, do not modify the article in such a way as to damage the author's honor or reputation, and license their new adaptations or creations under identical terms (CC BY-NC-SA).

    Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND): for non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

    To provide open access, this journal has an open access fee (also known as: open access publication fee) which needs to be met by the authors or their research funders. The open access fee is all inclusive, Elsevier will not add any additional charges. Depending on local regulations VAT can be charged by local authorities.

    Because Translational Proteomics is a HUPO-affiliated journal, HUPO members are always entitled to a 25% discount off of the standard Translational Proteomics Open Access author fees of $1950 (excluding taxes). The submitting author will be asked at the time of submission to check an additional box if they a HUPO member. Elsevier will confirm with HUPO that the author is indeed a HUPO member and the discount will be applied at the time of publication.

    Language (usage and editing services)

    Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop (http://webshop.elsevier.com/languageediting/) or visit our customer support site (http://support.elsevier.com) for more information.

    Submission

    Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts source files to a single PDF file of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF files at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail removing the need for a paper trail.

    Submit your article
    Please submit your article via http://ees.elsevier.com/trprot.

    Referees

    Please provide the names and addresses of 4 - 5 suitable potential reviewers. If there are compelling reasons for excluding some individuals as potential reviewers, these can be mentioned. However, choice of reviewers is at the Editors' discretion.

    NEW SUBMISSIONS

    Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.
    As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or lay-out that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

    References

    There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

    Formatting requirements

    There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.
    If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.
    Divide the article into clearly defined sections.

    Figures and tables embedded in text
    Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file.

    REVISED SUBMISSIONS

    To assist in the reviewing of your paper, please add line numbering to your manuscript file.

    Use of word processing software
    Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: http://www.elsevier.com/guidepublication). See also the section on Electronic artwork.
    To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

    Article structure

    Original articles are usually divided into the sections Introduction, Materials and methods, Results, Discussion and Conclusions:

    Introduction
    This is a short section in which the authors should state the reasons for performing the work, with brief reference to relevant previous work.

    Material and methods
    Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

    Results
    Results should be clear and concise.

    Discussion
    This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

    Conclusions
    The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

    News & Views and Letters to the Editor are not divided into sections after the summary, except for the reference list. The first paragraph serves as an introduction; acknowledgements are added as a final paragraph before the reference list.

    Experimental design data analysis for clinical and proteomics-based experiments:
    The experimental design must be provided and must include details of the number of biological and analytical replicates and qualitative and quantitative measurement reproducibility. In clinical studies, it is mandatory to provide the STARD checklist and flow diagram for reporting of studies of diagnostic accuracy, the CONSORT checklist for randomized trials, the REMARK checklist for prognostic studies and any appropriate reporting guidelines.


    For expression analysis studies, the appropriate Minimum Information for Biological and Biomedical Investigation (MIBBI) checklist(s) should be provided (MIAPE, MIAME, MIAPAR, MIARE, MIASPPE, MIMIx, MIGen, MINI, MIQE, MINSEQE, MIQAS, MIxS, BioDBCore, . . . ).


    Authors must report the following: methods of data normalization, transformation, missing value handling, the statistical tests used, the degrees of freedom, justification of outliers removal and the statistical package or program used. Where biologically important differences in omics expression are reported, orthogonal confirmatory data are mandatory. The method(s) used to generate the mass spectrometry data must be described. The name and version of the program used for database searching, the values of critical search parameters (e.g. the mass over charge (m/z) and the charge (z) of the precursor ion, fragment mass tolerance, cleavage rules used, allowance for number of missed cleavages, fixed and variable modifications) and the name and version of the database(s) searched must be provided with number of protein entries in the database. The number of unique peptides used to identify a protein must be given as well as the sequence and charge state of each peptide. For each protein identified, measures of certainty (e.g. FDR, p-values), the sequence coverage and the accession number must be provided. The score value for accepting single MS/MS spectra should be provided. How redundancy and isoforms are handled must be provided.


    For experiments with large MS/MS data sets, estimates of the false positive rates are required (e.g. through searching randomized or reversed sequence databases). This information should be provided as supporting information. Where post-translational modifications are reported, the methods used to discover the modification must be described. The modification should be mapped to amino acid(s) by fragmentation analysis, but reported as ambiguous if mapping to a single amino acid is not possible. For isobaric modifications, evidence for assigning a specific modification must be provided and the spectra included as supporting information. Where protein sequence isoforms are reported, the peptide sequence that matches the unique amino acid sequence of a particular isoform must be provided. Fragmentation analysis of the appropriate peptides should be described.


    Identification of proteins based solely on mass fingerprinting will not be considered. Identification of proteins from organisms with unknown genome sequence will be accepted only if MS/MS-derived peptide sequence data have been used for database searching or BLAST analysis. The score for the highest ranked hit to a homologous, orthologous, or paralogous protein should be indicated.

    In addition to the above mentioned checklist, Translational Proteomics also requires its own checklist for identification and quantification of peptides and/or proteins by Mass Spectrometry (download word file here here)

    Essential title page information

    Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
    Author names and affiliations. Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
    Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. Ensure that phone numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding author.
    Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

    Graphical abstract

    A Graphical abstract is mandatory for this journal. It should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership online. Authors must provide images that clearly represent the work described in the article. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. See http://www.elsevier.com/graphicalabstracts for examples.
    Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images also in accordance with all technical requirements: Illustration Service.

    A Graphical Abstract should allow readers to quickly gain an understanding of the main take-home message of the paper and is intended to encourage browsing, promote interdisciplinary scholarship, and help readers identify more quickly which papers are most relevant to their research interests. The Graphical Abstract should summarize the contents of the paper in a concise, pictorial form designed to capture the attention of a wide readership. Authors must provide images that clearly represent the work described in the paper. A key, summarising figure taken from the original paper can also be submitted as a graphical abstract.


    Graphical Abstracts should be submitted as a separate file in EES by selecting "Graphical Abstract" from the drop-down box when uploading files.

    Highlights

    Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). See http://www.elsevier.com/highlights for examples.

    Footnotes

    Footnotes should be used sparingly. Number them consecutively throughout the article. Many wordprocessors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.
    Table footnotes
    Indicate each footnote in a table with a superscript lowercase letter.

    Artwork

    Electronic artwork
    General points
    • Make sure you use uniform lettering and sizing of your original artwork.
    • Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
    • Number the illustrations according to their sequence in the text.
    • Use a logical naming convention for your artwork files.
    • Indicate per figure if it is a single, 1.5 or 2-column fitting image.
    • For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
    • Please note that individual figure files larger than 10 MB must be provided in separate source files.
    A detailed guide on electronic artwork is available on our website:
    http://www.elsevier.com/artworkinstructions.
    You are urged to visit this site; some excerpts from the detailed information are given here.
    Formats
    Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
    EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.
    TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.
    TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.
    TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.
    Please do not:
    • Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
    • Supply files that are too low in resolution.
    • Submit graphics that are disproportionately large for the content.

    Color artwork
    Please make sure that artwork files are in an acceptable format (TIFF, EPS or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color on the Web (e.g., ScienceDirect and other sites). For further information on the preparation of electronic artwork, please see http://www.elsevier.com/artworkinstructions.

    Figure captions
    Ensure that each illustration has a caption. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

    Tables

    Number tables consecutively in accordance with their appearance in the text. Place footnotes to tables below the table body and indicate them with superscript lowercase letters. Avoid vertical rules. Be sparing in the use of tables and ensure that the data presented in tables do not duplicate results described elsewhere in the article.

    References

    Citation in text
    The numerical system of references should be used. References in the text should be cited by numbers in square brackets in the order of their citation.


    References are listed together in their order of appearance in a separate section at the end of the text under the heading References. All references should be numbered consecutively. References to journals should contain initials and names of all authors, article title, abbreviation of the name of the journal according to the List of Serial Title World Abbreviations (International Series Data System, 20, rue Bachaumont, 75002 Paris, France. ISBN 2-904938-02-8), year of publication, volume number, and page numbers. References to books should also include the title (of series and volumes), initials and names of the editor(s), the publisher and place of publication.


    Examples:


    Reference to a journal publication:
    [1] Resing KA, Ahn NG. Proteomics strategies for protein identification. FEBS Letters 2005;579:885-9.


    Reference to a book:
    [2] Rehm H. Protein Biochemistry and Proteomics. San Diego: Academic Press/Elsevier Inc; 2006.


    Reference to a chapter in an edited book or book series:
    [3] Morgan JW, Hettick JM, Russell DH. Peptide sequencing by MALDI 193-nm photodissociation TOF MS. In: Burlingame AL, editor. Methods in Enzymology, vol 402: Biological Mass Spectrometry. San Diego: Academic Press/Elsevier Inc; 2005, p.186-209.


    Reference to a paper as "in press" implies that it has been accepted for publication. Evidence (e.g., a photocopy of the note of acceptance from the journal concerned) should accompany the submitted typescript. Papers that are "in press" should be included as a number in the text. Other papers submitted before or simultaneously with the paper in question should be included as a number in the text and in the References section, stating the name of the journal. Copies of papers that are submitted elsewhere should be provided for inspection by the Editors. Omission of this information will delay publication and may lead to redating of a submitted manuscript. Papers presented at scientific meetings that are not available in published form should not be cited as references in the References section.


    Unpublished results should not be listed in the References section. In the text they are mentioned as follows: "(Tervoort MV and Glimcher J, unpublished data)". When unpublished results are cited, the data should be provided for the Editors' information when essential for proper evaluation, or if requested.


    A personal communication should be mentioned in the text as follows: "(Tervoort MV, personal communication)". Authors should not make unauthorized use of personal communications. Personal communications are not to be included in the Reference section.

    Reference formatting
    There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

    Reference management software

    This journal has standard templates available in key reference management packages EndNote (http://www.endnote.com/support/enstyles.asp) and Reference Manager (http://refman.com/support/rmstyles.asp). Using plug-ins to wordprocessing packages, authors only need to select the appropriate journal template when preparing their article and the list of references and citations to these will be formatted according to the journal style which is described below.

    Video data

    Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at http://www.elsevier.com/artworkinstructions. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content. Files can be stored on diskette, ZIP-disk or CD (either MS-DOS or Macintosh).

    AudioSlides

    The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at http://www.elsevier.com/audioslides. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

    Supplementary data

    Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at http://www.elsevier.com/artworkinstructions.

    Submission checklist

    The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.
    Ensure that the following items are present:
    One author has been designated as the corresponding author with contact details:
    • E-mail address
    • Full postal address
    • Telephone
    All necessary files have been uploaded, and contain:
    • Keywords
    • All figure captions
    • All tables (including title, description, footnotes)
    Further considerations
    • Manuscript has been 'spell-checked' and 'grammar-checked'
    • All references mentioned in the Reference list are cited in the text, and vice versa
    • Permission has been obtained for use of copyrighted material from other sources (including the Web)
    • Color figures are clearly marked as being intended for color reproduction on the Web (free of charge) and in print, or to be reproduced in color on the Web (free of charge) and in black-and-white in print
    • If only color on the Web is required, black-and-white versions of the figures are also supplied for printing purposes
    For any further information please visit our customer support site at http://support.elsevier.com.

    For any further information please visit our customer support site at http://support.elsevier.com.

    Additional Information

    Line numbers have been added to your manuscript file.

    Use of the Digital Object Identifier

    The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal Physics Letters B):
    http://dx.doi.org/10.1016/j.physletb.2010.09.059
    When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

    Online proof correction

    Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.
    If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.
    We will do everything possible to get your article published quickly and accurately - please upload all of your corrections within 48 hours. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.

    Offprints

    The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use.

    Offprints

    The corresponding author, at no cost, will be provided with a personalized link providing 50 days free access to the final published version of the article on ScienceDirect. This link can also be used for sharing via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's WebShop (http://webshop.elsevier.com/myarticleservices/offprints). Authors requiring printed copies of multiple articles may use Elsevier WebShop's 'Create Your Own Book' service to collate multiple articles within a single cover (http://webshop.elsevier.com/myarticleservices/booklets).

    Standard abbreviations

    Standard abbreviations allowed to be used without explanation or definition in all articles published in Translational Proteomics.

    A absorbance
    ACES 2-[(2-amino-2-oxoethyl)amino] ethanesulphonic acid
    CAN acetonitrile
    A/D analog to digital converter
    AEBSF 4-(2-aminoethyl)benzenesulphonyl fluoride
    amu atomic mass unit
    ANOVA analysis of variance
    API atmospheric pressure ionization
    AUC area under curve
    Bis N,N'-methylenebisacrylamide
    bp base pairs
    BSA bovine serum albumin
    %C cross-linking agent (g/100 mL)/%T
    CAPS 3-(cyclohexylamino)-1-propanesulphonic acid
    CBB Coomassie Brilliant Blue
    CCD charge-coupled device
    CD circular dicroism
    CE capillary electrophoresis
    CEC capillary electrochromatography
    CFE continuous flow electrophoresis
    CHAPS 3-[(3-cholamidopropyl)dimethylamonio]-1-propanesulphonate
    CHCA ?-cyano-4-hydroxycinnamic acid
    CHES 2-(N-cyclohexylamino)ethanesulphonic acid
    CID collision-induced dissociation
    CIEF capillary isoelectric focusing
    CMC critical micelle concentration
    Con A Concanavalin A
    CNS central nervous system
    cpm counts per minute
    CTAB etyltrimethylammonium bromide
    CV coefficient of variation
    CZE capillary zone electrophoresis
    1-D one-dimensional
    2-D two-dimensional
    Da dalton (molecular mass)
    2-DE two-dimensional electrophoresis
    DIGE fluorescence difference gel electrophoresis
    DGGE denaturing gradient gel electrophoresis
    DMEM Dulbecco's modified Eagle medium
    DMF N,N-dimethylformamide
    DMSO dimethyl sulphoxide
    DOC sodium deoxycholate
    dsDNA double-stranded DNA
    DTE dithioerithriol
    DTT dithiothreitol
    ECL enhanced chemiluminescence
    EDTA ethylenediaminetetraacetic acid
    EEO electroendosmosis
    EGTA ethylene glycol-bis(?-aminoethylether)-N,N,N',N'-tetraacetic acid
    EKC electrokinetic chromatography
    ELISA enzyme-linked immunosorbent assay
    EMSA electrophoretic mobility shift assay
    EOF electroosmotic flow
    ER endoplasmic reticulum
    ESI electrospray ionization
    EST expressed sequence tag
    EUPA European Proteome Association
    FAB fast atom bombardment
    FACS fluorescence activated cell sorting
    FBS fetal bovine serum
    FCS fetal calf serum
    FIGE field inversion gel electrophoresis
    FITC fluorescein isothiocyanate
    FT Fourier transform
    FT-ICR Fourier transform-ion cyclotron resonance
    GC gas chromatography
    GIF graphic interchange format
    GRAVY grand average hydrophobicity
    GSH glutathione
    GST glutathione-S-transferase
    HE hematoxylin and eosin
    HEPES N-(2-hydroxyethyl)piperazine-2'-(2-ethanesulphonic acid)
    HPCE high-performance capillary electrophoresis
    HPLC high-performance liquid chromatography
    HRP horseradish peroxidase
    HSA human serum albumin
    HSP heat shock protein
    HTML hypertext mark-up language
    HUPO Human Proteome Organisation
    HVR hypervariable region
    ICAT isotop-coded affinity tag
    ICR ion cyclotron resonance
    id inside diameter
    IEF isoelectric focusing
    Ig immunoglobulin
    IMAC immobilized metal affinity capture
    IPG immobilized pH gradient
    IT ion trap
    iTRAQ isobaric tag for relative and absolute quantitation
    kbp kilobase pairs
    kDa kilodalton (molecular mass)
    LC liquid chromatography
    LED light-emitting diode
    LOD limit of detection
    LOQ limit of quantitation
    mAb monoclonal antibody
    MALDI-MS matrix-assisted laser-desorption ionization-mass spectrometry
    Mbp megabase


    MEKC micellar electrokinetic capillary chromatography
    MES 2-(N-morpholino)ethanesulphonic acid
    MHC major histocompatibility complex
    MOPS 3-(N-morpholino)propanesulphonic acid
    Mr relative molecular mass (dimensionless)
    MS mass spectrometry
    MS/MS tandem mass spectrometry
    MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
    m/z mass-to-charge ratio
    NC nitrocellulose NEPHGE nonequilibrium pH gradient electrophoresis
    NMR nuclear magnetic resonance
    NP-40 Nonidet P-40
    od outside diameter
    OD optical density
    OFAGE orthogonal field alternation gel electrophoresis
    ORF open reading frame
    PAGE polyacrylamide gel electrophoresis
    PBS phosphate-buffered saline
    PCR polymerase chain reaction
    PDMS polydimethylsiloxane
    PED pulsed electrochemical detection PEG polyethylene glycol
    PFGE pulsed-field gel electrophoresis
    PFU plaque-forming units
    pI isoelectric point
    PMF peptide mass fingerprinting
    PMS phenazine methosulphate
    PMSF phenylmethylsulphonyl fluoride
    PMT photomultiplier tube
    PSD post-source decay
    PTFE polytetrafluoroethylene
    PTH phenylthiohydantoin
    PTM post-translational modification
    PVA polyvinyl alcohol
    PVDF polyvinylidene difluoride
    PVP polyvinylpyrrolidone
    Q-TOF quadrupole time-of-flight
    RACE rapid amplification of cDNA ends
    RFLP restriction fragment length polymorphism
    RIA radioimmunoassay
    ROS reactive oxygen species
    RP reversed phase
    rpm revolutions per minute
    RSD relative standard deviation
    RT-PCR reverse transcriptase-PCR
    SAGE serial analysis of gene expression
    SD standard deviation
    SDS sodium dodecyl sulphate
    SEC size-exclusion chromatography
    SELDI surface-enhanced laser desorption/ionization
    SEM standard error of the mean
    SIM selected ion monitoring
    S/N signal-to-noise ratio
    SPE solid-phase extraction
    SPR surface plasmon resonants
    SSCP single-strand conformation polymorphism
    ssDNA single-stranded DNA
    SSP sample spot number
    STR short tandem repeat
    %T total gel concentration (acrylamide plus cross-linking agent; g/100 mL)
    TBS Tris-buffered saline
    TCA trichloroacetic acid
    TEMED N,N,N',N'-tetramethylethylenediamine
    TFA trifluoroacetic acid
    THF tetrahydrofuran
    TIC total ion current
    TLC thin-layer chromatography
    TNF tumour necrosis factor
    TOF time of flight
    Tris tris(hydroxymethyl)aminomethane
    TRITC tetramethylrhodamine isothiocyanate
    URL uniform resource locator
    UTR untranslated region
    UV ultraviolet
    Vh volt ×hours
    z ion charge



    You can track your submitted article at http://help.elsevier.com/app/answers/detail/a_id/89/p/8045/. You can track your accepted article at http://www.elsevier.com/trackarticle. You are also welcome to contact Customer Support via http://support.elsevier.com.

Advertisement

advert image